mva-pp
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2006 (NCT00374998)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mva-pp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00375128 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2006 | European Malaria Vaccine Initiative, United States Army, University of Oxford, Wellcome Trust |
| NCT00374998 | Phase 1 | Apr 1, 2006 | European Malaria Vaccine Initiative, University of Oxford, Wellcome Trust |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| European Malaria Vaccine Initiative | Academic/Hospital | 2 | 2 | 2 | 2006 |
| University of Oxford | Academic/Hospital | 2 | 0 | 2 | 2006 |
| Wellcome Trust | Academic/Hospital | 2 | 0 | 2 | 2006 |
| United States Army | Government | 1 | 0 | 1 | 2006 |
4 organizations
Page 1 / 1